Celltrion Inc
KRX:068270
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
157 600
231 500
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Celltrion Inc
Celltrion Inc
Total Equity
Celltrion Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Celltrion Inc
KRX:068270
|
Total Equity
₩17T
|
CAGR 3-Years
67%
|
CAGR 5-Years
45%
|
CAGR 10-Years
31%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Total Equity
₩1.7T
|
CAGR 3-Years
86%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Green Cross Corp
KRX:006280
|
Total Equity
₩1.3T
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Total Equity
₩817.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Total Equity
₩480.8B
|
CAGR 3-Years
21%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Equity
₩177.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Celltrion Inc
Glance View
Celltrion Inc. is a South Korean biopharmaceutical company that has made significant strides in the development and commercialization of biosimilars, monoclonal antibodies, and novel therapeutics. Established in 2002, the company has positioned itself as a key player in the global pharmaceutical landscape, particularly known for its commitment to making biological drugs more accessible and affordable. With a robust pipeline of products targeting conditions such as autoimmune diseases, cancer, and infectious diseases, Celltrion leverages state-of-the-art biotechnology and a strong emphasis on research and development. This focus not only enhances its product offerings but also champions the company’s mission of improving patient outcomes worldwide. As the global market for biosimilars continues to expand, driven by increasing healthcare costs and an aging population, Celltrion stands at the forefront, equipped with a solid operational framework and a strategic partnership approach. The company’s flagship products, like Remsima, a biosimilar to Remicade, have achieved notable success, gaining approval in numerous countries and establishing a strong revenue stream. With its plans to diversify its product portfolio, including innovative therapies in oncology, Celltrion is poised for growth. For investors, this translates into a promising opportunity to tap into a company that not only prioritizes innovation but also operates within a rapidly evolving market characterized by increasing demand for more affordable biologics.
See Also
What is Celltrion Inc's Total Equity?
Total Equity
17T
KRW
Based on the financial report for Jun 30, 2024, Celltrion Inc's Total Equity amounts to 17T KRW.
What is Celltrion Inc's Total Equity growth rate?
Total Equity CAGR 10Y
31%
Over the last year, the Total Equity growth was 299%. The average annual Total Equity growth rates for Celltrion Inc have been 67% over the past three years , 45% over the past five years , and 31% over the past ten years .
You don't have any saved screeners yet
